In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

While some of his allies have lamented that Biden's legacy as president has been reduced to questions of his declining health and mental acuity, many Democrats are still bitter about Biden's 2024 ...

The cancer treatment that has been hiding in plain sightBy Tim BakerIf you take even a passing interest in the world of cancer research, you could've ...

Eighty-five original research projects from aspiring physician-scientists were on display at the 2026 Medical Student Research Forum at the Jacobs School of Medicine and Biomedical Sciences.